Dell Services Named Founding Health Care IT Partner for The Innovation Institute

PLANO, Texas & NEWPORT BEACH, Calif. Aug. 4, 2015 - The Innovation Institute announced that Dell Services has agreed to become the founding health care information technology partner of The Institute’s Innovation Lab in Newport Beach, Calif.

The Innovation Institute, world-class corporate health-care incubator, is structured to facilitate innovation among inventors, health care plan providers, medical facilities, physicians and employees across major health care organizations. Through its Innovation Lab, medical product and solution ideas are vetted and the best ones are developed further and introduced into the health care marketplace.

Dell will leverage The Innovation Institute to look at new solutions and ideas, facilitate pilot programs and gain access to clinical expertise via The Institute’s team of world-class experts. The two organizations will work together to create new use cases and solutions with the goal of improving outcomes for the health care marketplace.

Dell plans to engage with The Innovation Institute in a number of pilot programs including:

  • Cloud-enabled analytics and how to turn health care data into actionable knowledge and insights for better decision-making
  • Patient engagement to better connect and deepen relationships with patients; and
  • Dell Internet of Things (IoT) to bring the power of analytics to the edge of the network, reducing the time and cost associated with transferring non-essential data to the cloud

“Investing in innovation enables us to build solutions that address the needs of the rapidly changing health care market. Working with The Innovation Institute gives Dell access to its members’ expertise, which will help us mature our capabilities and ultimately create better outcomes for our customers and the industry as a whole,” said Sid Nair, vice president and global general manager, Healthcare & Life Sciences, Dell Services.

“Dell has an impressive track record as the global leader in health care technology,” said The Innovation Institute President and CEO Joe Randolph. “When we combine our resources with Dell’s, I believe that together we’ll develop information technology breakthroughs that are needed to move care delivery forward.”

Dell continues to expand its commitment in health care its end-to-end integrated solutions combining services, software and hardware—including patient engagement, predictive analytics, health care cloud and interoperability, clinical applications management as well as managed infrastructure, application and business process services. Dell has earned the No. 1 ranking in Healthcare Provider Services for six consecutive years from Gartner1.

About The Innovation Institute
The Innovation Institute is an independent, for-profit LLC structured to cultivate innovative solutions to transform healthcare delivery. The Innovation Institute is owned by non-profit health systems. This collaborative taps into physicians, employees, and industry business partners to incubate and commercialize new medical products and ideas. Comprised of three distinct elements – an innovation lab, an investment fund, and a shared services group (Enterprise Development Group), The Institute strives to “do more, with less, for more people.” For more information, visit www.ii4change.com.

About Dell
Dell Inc. listens to customers and delivers innovative technology and services that give them the power to do more. As one of the leading providers of end-to-end IT solutions for healthcare worldwide, Dell helps healthcare organizations to simplify administration; coordinate and manage patient care; transition from episodic care to prevention and wellness management; and ultimately to deliver personalized medicine. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.